Formulated PSTA Injection Versus PATA Alone in the Management of Macular Edema Secondary to Non-ischemic Retinal Vein Occlusions
Launched by AL-AZHAR UNIVERSITY · May 18, 2022
Trial Information
Current as of August 02, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Diminution vision due to macular edema secondary to non-ischemic retinal vein occlusions, either central or branch, as evidenced by clinical and angiographic evaluation
- • CMT ≥ 250 µ.
- • Willing to participate in the study
- Exclusion Criteria:
- • Unwilling to participate in the study.
- • Ischemic RVO
- • Prior laser treatment
- • Glaucoma/Ocular Hypertension
- • Cataract which lead to difficulty in the evaluation of macula
- • Vitreous hemorrhage
- • Macular ischemia
- • Iris neovascularisation
- • patients with intravitreal injection of anti VEGFs, steroid, or any intraocular surgery 3 months prior to the inclusion.
About Al Azhar University
Al-Azhar University, a prestigious institution in Egypt, is dedicated to advancing medical research and education through rigorous clinical trials. With a strong emphasis on ethical standards and scientific integrity, the university aims to contribute to the development of innovative therapies and healthcare solutions. By fostering collaboration among researchers, healthcare professionals, and academic experts, Al-Azhar University positions itself as a leading sponsor in clinical research, committed to improving patient outcomes and enhancing the understanding of various medical conditions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Damieta, New Damietta, Egypt
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials